These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

402 related items for PubMed ID: 30850916

  • 1. Effects of Teneligliptin on the Progressive Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes Mellitus in Open-Label, Marker-Stratified Randomized, Parallel-Group Comparison, Standard Treatment-Controlled Multicenter Trial (TOPLEVEL Study): Rationale and Study Design.
    Imazu M, Nakano A, Ito S, Hamasaki T, Kitakaze M, TOPLEVEL investigators and study coordinators.
    Cardiovasc Drugs Ther; 2019 Jun; 33(3):363-370. PubMed ID: 30850916
    [Abstract] [Full Text] [Related]

  • 2. Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study.
    Yamada H, Tanaka A, Kusunose K, Amano R, Matsuhisa M, Daida H, Ito M, Tsutsui H, Nanasato M, Kamiya H, Bando YK, Odawara M, Yoshida H, Murohara T, Sata M, Node K, PROLOGUE Study Investigators.
    Cardiovasc Diabetol; 2017 May 11; 16(1):63. PubMed ID: 28490337
    [Abstract] [Full Text] [Related]

  • 3. Association of glycemic variability with left ventricular diastolic function in type 2 diabetes mellitus.
    Yokota S, Tanaka H, Mochizuki Y, Soga F, Yamashita K, Tanaka Y, Shono A, Suzuki M, Sumimoto K, Mukai J, Suto M, Takada H, Matsumoto K, Hirota Y, Ogawa W, Hirata KI.
    Cardiovasc Diabetol; 2019 Dec 05; 18(1):166. PubMed ID: 31805945
    [Abstract] [Full Text] [Related]

  • 4. Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes.
    Hashikata T, Yamaoka-Tojo M, Kakizaki R, Nemoto T, Fujiyoshi K, Namba S, Kitasato L, Hashimoto T, Kameda R, Maekawa E, Shimohama T, Tojo T, Ako J.
    Heart Vessels; 2016 Aug 05; 31(8):1303-10. PubMed ID: 26266630
    [Abstract] [Full Text] [Related]

  • 5. Effects of empagliflozin in different phases of diabetes mellitus-related cardiomyopathy: a prospective observational study.
    Oka S, Kai T, Hoshino K, Watanabe K, Nakamura J, Abe M, Watanabe A.
    BMC Cardiovasc Disord; 2021 Apr 29; 21(1):217. PubMed ID: 33926386
    [Abstract] [Full Text] [Related]

  • 6. Rationale and Design of the Multicenter Trial on Japan Working Group on the Effects of Angiotensin Receptor Blockers Selection (Azilsartan vs. Candesartan) on Diastolic Function in the Patients Suffering from Heart Failure with Preserved Ejection Fraction: J-TASTE Trial.
    Takahama H, Asakura M, Abe Y, Ajioka M, Aonuma K, Anzai T, Hayashi T, Hiramitsu S, Kawai H, Kioka H, Kimura K, Lim YJ, Matsuoka K, Motoki H, Nagata Y, Nakamura S, Ohte N, Ozaki Y, Sasaoka T, Tamaki S, Hamasaki T, Kitakaze M, J-TASTE investigators.
    Cardiovasc Drugs Ther; 2018 Aug 29; 32(4):381-388. PubMed ID: 29974299
    [Abstract] [Full Text] [Related]

  • 7. Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial.
    Bizino MB, Jazet IM, Westenberg JJM, van Eyk HJ, Paiman EHM, Smit JWA, Lamb HJ.
    Cardiovasc Diabetol; 2019 Apr 30; 18(1):55. PubMed ID: 31039778
    [Abstract] [Full Text] [Related]

  • 8. Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes.
    Matsutani D, Sakamoto M, Kayama Y, Takeda N, Horiuchi R, Utsunomiya K.
    Cardiovasc Diabetol; 2018 May 22; 17(1):73. PubMed ID: 29788955
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Coronary microvascular function is independently associated with left ventricular filling pressure in patients with type 2 diabetes mellitus.
    Kawata T, Daimon M, Miyazaki S, Ichikawa R, Maruyama M, Chiang SJ, Ito C, Sato F, Watada H, Daida H.
    Cardiovasc Diabetol; 2015 Aug 05; 14():98. PubMed ID: 26242308
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Impact of left ventricular longitudinal functional mechanics on the progression of diastolic function in diabetes mellitus.
    Mochizuki Y, Tanaka H, Matsumoto K, Sano H, Shimoura H, Ooka J, Sawa T, Motoji Y, Ryo-Koriyama K, Hirota Y, Ogawa W, Hirata KI.
    Int J Cardiovasc Imaging; 2017 Dec 05; 33(12):1905-1914. PubMed ID: 28642993
    [Abstract] [Full Text] [Related]

  • 13. Effects of Dipeptidyl Peptidase-4 Inhibitor Linagliptin on Left Ventricular Dysfunction in Patients with Type 2 Diabetes and Concentric Left Ventricular Geometry (the DYDA 2™ Trial). Rationale, Design, and Baseline Characteristics of the Study Population.
    Giorda CB, Cioffi G, Lucci D, Nada E, Ognibeni F, Mancusi C, Latini R, Maggioni AP, DYDA 2 Investigators.
    Cardiovasc Drugs Ther; 2019 Oct 05; 33(5):547-555. PubMed ID: 31418140
    [Abstract] [Full Text] [Related]

  • 14. Impact of glycemic control on aortic stiffness, left ventricular mass and diastolic longitudinal function in type 2 diabetes mellitus.
    Kozakova M, Morizzo C, Fraser AG, Palombo C.
    Cardiovasc Diabetol; 2017 Jun 17; 16(1):78. PubMed ID: 28623932
    [Abstract] [Full Text] [Related]

  • 15. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure.
    Soga F, Tanaka H, Tatsumi K, Mochizuki Y, Sano H, Toki H, Matsumoto K, Shite J, Takaoka H, Doi T, Hirata KI.
    Cardiovasc Diabetol; 2018 Oct 08; 17(1):132. PubMed ID: 30296931
    [Abstract] [Full Text] [Related]

  • 16. Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial.
    Kusunose K, Imai T, Tanaka A, Dohi K, Shiina K, Yamada T, Kida K, Eguchi K, Teragawa H, Takeishi Y, Ohte N, Yamada H, Sata M, Node K, CANDLE Trial Investigators.
    Cardiovasc Diabetol; 2021 Sep 14; 20(1):186. PubMed ID: 34521417
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study.
    Kadowaki T, Inagaki N, Kondo K, Nishimura K, Kaneko G, Maruyama N, Nakanishi N, Gouda M, Iijima H, Watanabe Y.
    Diabetes Obes Metab; 2018 Feb 14; 20(2):453-457. PubMed ID: 28786530
    [Abstract] [Full Text] [Related]

  • 18. Identification of a definite diabetic cardiomyopathy in type 2 diabetes by comprehensive echocardiographic evaluation: A cross-sectional comparison with non-diabetic weight-matched controls.
    Ofstad AP, Urheim S, Dalen H, Orvik E, Birkeland KI, Gullestad L, W Fagerland M, Johansen OE, Aakhus S.
    J Diabetes; 2015 Nov 14; 7(6):779-90. PubMed ID: 25350248
    [Abstract] [Full Text] [Related]

  • 19. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.
    Kadowaki T, Kondo K.
    Diabetes Obes Metab; 2013 Sep 14; 15(9):810-8. PubMed ID: 23464664
    [Abstract] [Full Text] [Related]

  • 20. Diagnosis of Nonischemic Stage B Heart Failure in Type 2 Diabetes Mellitus: Optimal Parameters for Prediction of Heart Failure.
    Wang Y, Yang H, Huynh Q, Nolan M, Negishi K, Marwick TH.
    JACC Cardiovasc Imaging; 2018 Oct 14; 11(10):1390-1400. PubMed ID: 29778859
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.